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Fig 1. Collodion baby. Tight, shiny film or dried collodion
reminiscent of the skin of a sausage covers the entire
surface of this 2-day-old neonate whose mother was
treated with infliximab throughout her pregnancy.
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Collodion-like membrane in a newborn
exposed to infliximab
To the Editor: A 2-day-old black female newborn,
born via cesarean section after premature rupture of
membranes (34 weeks’ gestation), had a collodion
membrane. Stellate cracking was present over the
entire cutaneous surface (Fig 1). There were no nail
abnormalities, bullae, ectropion, or eclabium. The
mother was treated for severe psoriasis and psoriatic
arthritis with a 7.5-mg/kg infusion of infliximab
every 6 weeks throughout pregnancy, and for 6
months before conception. She took no other
medications during her pregnancy. Newborn
genetic screening, complete blood cell count, and
comprehensive metabolic panel test results were
within normal limits, and there was no history
of consanguinity. There was no family history
of bullous congenital ichthyosiform erythroderma
or lamellar ichthyosis. Treatment was initiated with
a petrolatum-based ointment (Aquaphor, Beiersdorf
Inc, Wilton, CT). The collodion membrane shed
completely and the skin normalized over 2 months.
The skin was normal-appearing at age 1 year.
The mean age of onset of psoriasis is during
the 20s and 30s, the peak childbearing years.
Although the hormonal changes of pregnancy can
improve psoriasis, approximately 20% worsen.1
Psoriatic arthritis, severe in 5% of patients, can be
quite destructive. Inflammatory cytokines such as
interleukin 17 and tumor necrosis factor (TNF)-alfa
inhibit the T-helper cell type 17 axis inducingOpen access under CC BY-NC-ND license.inflammation and defects in keratinocyte differen-
tiation producing psoriatic plaques.2 TNF-alfa
inhibitors, such as infliximab, are remarkably
effective in controlling both psoriasis and psoriatic
arthritis.2
Infliximab, a complete chimeric monoclonal IgG1
antibody, is a potent antieTNF-alfa biologic agent
delivered by infusion. It is designated Food and
Drugs Administration (FDA) category B because
animal reproduction studies did not demonstrate a
risk but well-controlled studies in human pregnancy
have not been done.3 The Fc receptors on
trophoblasts help to actively transport all biological
agents with an IgG Fc region. Therefore, the
transplacental passage of monoclonal antibodies
such as infliximab and adalimumab is greater than
in etanercept.
An FDA database review of 41 children born
to mothers taking a TNF antagonist demonstrated
congenital anomalies in 24 children (59%).3 Of the
anomalies reported, 56% were part of the vertebral
defects, anal atresia, cardiac defects, tracheoesopha-
geal fistula, renal anomalies, and limb abnormalities
(VACTERL) spectrum, but only 1 child was diagnosed
with VACTERL. A retrospective analysis of pregnancy
outcomes of 32 women exposed to antieTNF-alfa
inhibitors demonstrated no increased risk to the
patients and fetuses, although the paucity of data
precluded a recommendation for regular use in
pregnancy.4
Although collodion membrane associated with
antieTNF biologic agents has not been reported to
our knowledge, there are several examples of
paradoxical inducement of keratinization abnorma-
lities. New-onset psoriasis has occurred in a series of
patients with rheumatologic conditions treated
with TNF-alfa inhibitors.5,6 The pathogenesis of
these paradoxical reactions may be the result of
overexpression of interferon because of the
cross-regulation between TNF-alfa and interferon.
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Letters e23Perhaps a similar mechanism may explain the
translucent, tight, and parchment paperelike
‘‘collodion membrane’’ in our patient after prenatal
exposure to infliximab. Collodion membrane
secondary to ichthyoses can be excluded because
this child’s condition was self-limited. Considering
potential side effects of alternative systemic
agents, TNF-alfa inhibitors should remain in the
armamentarium for pregnant psoriatic patients.
Etanercept may be the safest of this class because
of its lower level transplacental passage.
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chemotherapy for radiation-induced
osteosarcoma
To the Editor: Chemotherapeutic agents have
numerous cutaneous adverse effects, including
hyperpigmentation, radiation recall, and extravasa-
tion injuries. Typically, hyperpigmentation reactions
are either diffuse (eg, the ‘‘busulfan tan’’) or localized
(eg, streaking over veins in fluorouracil).1 We
describe a patient that developed hyperpigmenta-
tion following chemotherapy for a radiation-induced
osteosarcoma.
A 47-year-old African Americanman presented for
management of a radiation-induced osteosarcoma.
Intracranial meningioma was originally diagnosed
and treated with a craniotomy in 1995, followed by
resection of recurrent meningioma in 1996 and
adjuvant radiation in 1999. In 2012, he presented
with an enlarging right orbital rim mass that was
treated with a craniotomy and orbitotomy. Pathology
showed osteoblastic osteosarcoma, likely secondary
to radiation therapy. His chemotherapy regimen
included 2 months of Adriamycin (doxorubicin)
and cisplatin, followed by methotrexate, ifosfamide,
and etoposide. Seventy-two hours following his
second dose of methotrexate, minimally pruritic
cutaneous changes developed on his lower extrem-
ities, which spread to the extensor arms and trunk.
Physical examination demonstrated symmetric
fine reticular and linear hyperpigmentation without
excoriations on the dorsal ankles, medial arms,
abdomen, and back, which on dermatoscopic
exam appeared to be surrounded by a halo of
erythematous macules (Fig 1, A). Punch biopsy
demonstrated epidermal dysmaturation with
numerous atypical keratinocytes and melanin depo-
sition within the epidermis and stratum corneum
(Fig 1, B). Given the mild inflammatory infiltrate
and melanin deposition, we treated with 0.1%
triamcinolone cream twice daily to reduce the
inflammation and lighten the pigment by inhibiting
melanocyte secretory function, similar to treatment
of postinflammatory hyperpigmentation. The lesions
resolved within 6 months.
Although a similar reticular, hyperpigmented
pattern has not been reported in association with
